Therapeutic applications of noncoding RNAs

Current Opinion in Cardiology

Volumn 30, Issue 3, 2015, Pages 213-221

  Latronico, Michael V G ^a   Condorelli, Gianluigi ^a,b,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CNR   (Italy)

Author keywords

heart; long noncoding RNAs; microRNAs

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LONG UNTRANSLATED RNA; MICRORNA; MYOSIN HEAVY CHAIN ALPHA; MYOSIN LIGHT CHAIN 2; PARVOVIRUS VECTOR; RNA POLYMERASE II; SMALL INTERFERING RNA; TROPONIN C; UNTRANSLATED RNA;

DOWN REGULATION; GENE CONTROL; GENE OVEREXPRESSION; GENETIC ENGINEERING; HEART FAILURE; HUMAN; IMMUNOGENICITY; INVERTED TERMINAL REPEAT; MOLECULAR GENETICS; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TISSUE SPECIFICITY; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS CAPSID; GENETICS; MOLECULARLY TARGETED THERAPY;

HEART FAILURE; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; RNA, LONG NONCODING; RNA, UNTRANSLATED;

EID: 84928569855     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000162     Document Type: Review

References (56)

1. Kumarswamy R, Thum T. Noncoding RNAs in cardiac remodeling and heart failure. Circ Res 2013; 113:676-689.
2. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest 2013; 123:11-18.
3. Condorelli G, Latronico MV, Cavarretta E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol 2014; 63:2177-2187.
4. Thum T. Noncoding RNAs and myocardial fibrosis. Nat Rev Cardiol 2014; 11:655-663.
5. Cloonan N, Wani S, Xu Q, et al. MicroRNAs and their isomiRs function cooperatively to target common biological pathways. Genome Biol 2011; 12:R126. doi: 10.1186/gb-2011-12-12-r126.
6. Gantier MP, McCoy CE, Rusinova I, et al. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res 2011; 39:5692-5703.
7. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438:685-689.
8. Chiu YL, Rana TM. siRNA function in RNAi: A chemical modification analysis. RNA 2003; 9:1034-1048.
9. Chen PY, Weinmann L, Gaidatzis D, et al. Strand-specific 50-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008; 14:263-274.
10. Montgomery RL, Yu G, Latimer PA, et al. MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med 2014; 6:1347-1356.
11. Lagana A, Acunzo M, Romano G, et al. miR-Synth: A computational resource for the design of multisite multitarget synthetic miRNAs. Nucleic Acids Res 2014; 42:5416-5425.
12. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137:1005-1017.
13. Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011; 19:1116-1122.
14. Miyazaki Y,Adachi H,Katsuno M, et al. Viraldelivery of miR-196aameliorates the SBMA phenotype via the silencing of CELF2. Nat Med 2012; 18:1136-1141.
15. Lovric J, Mano M, Zentilin L, et al. Terminal differentiation of cardiac and skeletal myocytes induces permissivity to AAV transduction by relieving inhibition imposed by DNA damage response proteins. Mol Ther 2012; 20:2087-2097.
16. Asokan A, Samulski RJ. An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Hum Gene Ther 2013; 24:906-913.
17. Pulicherla N, Shen S, Yadav S, et al. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther 2011; 19:1070-1078.
18. Bish LT, Sleeper MM, Reynolds C, et al. Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines. Hum Gene Ther 2011; 22:969-977.
19. Grimm D, Kay MA. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 2006; 13:563-575.
20. Gill DR, Pringle IA, Hyde SC. Progress and prospects: The design and production of plasmid vectors. Gene Ther 2009; 16:165-171.
21. Pacak CA, Sakai Y, Thattaliyath BD, et al. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther 2008; 6:13. doi: 10.1186/1479-0556-6-13.
22. Qiao C, Yuan Z, Li J, et al. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther 2011; 18:403-410.
23. Geisler A, Schon C, Grossl T, et al. Application of mutated miR-206 target sites enables skeletal muscle-specific silencing of transgene expression of cardiotropic AAV9 vectors. Mol Ther 2013; 21:924-933.
24. Penaud-Budloo M, Le Guiner C, Nowrouzi A, et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol 2008; 82:7875-7885.
25. Buchlis G, Podsakoff GM, Radu A, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012; 119:3038-3041.
26. Eulalio A, Mano M, Dal Ferro M, et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012; 492:376-381.
27. Ganesan J, Ramanujam D, Sassi Y, et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 2013; 127:2097-2106.
28. Quattrocelli M, Crippa S, Montecchiani C, et al. Long-term miR-669a therapy alleviates chronic dilated cardiomyopathy in dystrophic mice. J Am Heart Assoc 2013; 2:e000284. doi: 10.1161/JAHA.113.000284.
29. Karakikes I, Chaanine AH, Kang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2013; 2:e000078. doi: 10.1161/JAHA.113.000078.
30. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012; 11:860-872.
31. Hogan DJ, Vincent TM, Fish S, et al. AntimiRs competitively inhibit microRNAs in Argonaute complexes. PLoS One 2014; 9:e100951. doi: 10.1371/journal. pone.0100951.
32. Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006; 34:2294-2304.
33. Esau CC. Inhibition of microRNA with antisense oligonucleotides. Methods 2008; 44:55-60.
34. Stenvang J, Petri A, Lindow M, et al. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012; 3:1. doi: 10.1186/1758-907X-3-1.
35. Summerton J, Stein D, Huang SB, et al. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 1997; 7:63-70.
36. Egholm M, Buchardt O, Nielsen PE, Berg RH. Peptide nucleic acids (PNA). Oligonucleotide analogs with an achiral peptide backbone. J Am Chem Soc 1992; 114:1895-1897.
37. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999; 1489:69-84.
38. Ørom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006; 372:137-141.
39. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in nonhuman primates. Nature 2008; 452:896-899.
40. Obad S, dos Santos CO, Petri A, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011; 43:371-378.
41. Hullinger TG, Montgomery RL, Seto AG, et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 2012; 110:71-81.
42. Lennox KA, Owczarzy R, Thomas DM, et al. Improved performance of antimiRNA oligonucleotides using a novel non-nucleotide modifier. Mol Ther Nucleic Acids 2013; 2:e117. doi: 10.1038/mtna.2013.46.
43. Bernardo BC, Gao X-M, Winbanks CE, et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A 2012; 109:17615-17620.
44. Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA 2010; 16:2043-2050.
45. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13:613-618.
46. Wang K, Liu F, Zhou LY, et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 2014; 114:1377-1388.
47. Gumireddy K, Young DD, Xiong X, et al. Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 2008; 47:7482-7484.
48. Young DD, Connelly CM, Grohmann C, Deiters A. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J Am Chem Soc 2010; 132:7976-7981.
49. Tan SB, Huang C, Chen X, et al. Small molecular inhibitors of miR-1 identified from photocycloadducts of acetylenes with 2-methoxy-1,4-naphthalenequinone. Bioorg Med Chem 2013; 21:6124-6131.
50. Monroig PD, Chen L, Zhang S, Calin GA. Small molecule compounds targeting miRNAs for cancer therapy. Adv Drug Deliv Rev 2014; 81C: 104-116.
51. Gebhard C, Huard G, Kritikou EA, Tardif JC. Apolipoprotein B antisense inhibition-update on mipomersen. Curr Pharm Des 2013; 19:3132-3142.
52. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368:1685-1694.
53. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013; 31:577. doi: 10.1038/nbt0713-577.
54. Melchiorri D, Pani L, Gasparini P, et al. Regulatory evaluation of Glybera in Europe-two committees, one mission. Nat Rev Drug Discov 2013; 12:719. doi: 10.1038/nrd3835-c1.
55. Greenberg B, Yaroshinsky A, Zsebo KM, et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: The CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC Heart Fail 2014; 2:84-92.
56. Hartmann D, Thum T. MicroRNAs and vascular (dys)function. Vascul Pharmacol 2011; 55:92-105.